Literature DB >> 21837766

Increased nuchal translucency and normal karyotype: perinatal and pediatric outcomes at 2 years of age.

R Mula1, A Goncé, M Bennásar, M Arigita, E Meler, A Nadal, A Sánchez, F Botet, A Borrell.   

Abstract

OBJECTIVE: To assess the perinatal and pediatric outcomes up to 2 years of age in singleton karyotypically normal fetuses with increased nuchal translucency (NT) above the 99(th) percentile.
METHODS: Singleton fetuses with NT above the 99(th) percentile and normal karyotype scanned in our center from 2002 to 2006 were included. Work-up included first- and second-trimester anomaly scan, first- and second-trimester fetal echocardiography, and in selected cases infection screening and genetic testing. Among survivors, a pediatric follow-up up to 2 years of age was undertaken.
RESULTS: During this 4-year period, 171 singleton fetuses with NT above the 99(th) percentile and normal karyotype were included in the study. There were seven spontaneous fetal losses, 38 terminations of pregnancy and two postnatal deaths. Among the 124 (72.5%) survivors, 12 (9.7%) were born with structural abnormalities. Neurodevelopmental follow-up was completed in 108 (87.1%) of the 124 survivors and four (3.7%) showed moderate to severe impairment. Overall, a structural abnormality or genetic syndrome was diagnosed in 50 fetuses/newborns. Prenatal diagnosis was achieved for 83.8% (31/37) of the structural abnormalities and 69.2% (9/13) of the genetic syndromes. Interestingly, a single umbilical artery was found in six fetuses with no structural defects at birth, five of which had a long-term favorable outcome (4.5%), and in one 22q11 microdeletion syndrome was diagnosed at 2 years of age.
CONCLUSION: Singleton fetuses with an increased NT above the 99(th) percentile and normal karyotype showed a 63% intact survival. Long-term neurodevelopmental outcome among survivors did not appear to differ from that reported for the general population.
Copyright © 2011 ISUOG. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 21837766     DOI: 10.1002/uog.10059

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  7 in total

1.  Significance of septa in first trimester increased nuchal translucency thickness.

Authors:  Aytul Corbacioglu Esmer; Ibrahim Kalelioglu; Betul Keyif; Mehmet Ozsurmeli; Atıl Yüksel; Recep Has
Journal:  J Med Ultrason (2001)       Date:  2013-06-19       Impact factor: 1.314

2.  Pregnancy Outcome of Abnormal Nuchal Translucency: A Systematic Review.

Authors:  Nasibeh Roozbeh; Maryam Azizi; Leili Darvish
Journal:  J Clin Diagn Res       Date:  2017-03-01

3.  Case Report: Atypical Cornelia de Lange Syndrome.

Authors:  Vito Leanza; Gabriella Rubbino; Gianluca Leanza
Journal:  F1000Res       Date:  2014-01-31

4.  Prenatal diagnosis of 4953 pregnant women with indications for genetic amniocentesis in Northeast China.

Authors:  Rulin Dai; Yang Yu; Qi Xi; Xiaonan Hu; Haibo Zhu; Ruizhi Liu; Ruixue Wang
Journal:  Mol Cytogenet       Date:  2019-11-06       Impact factor: 2.009

5.  Neurodevelopmental outcome at 2 years of corrected age in fetuses with increased nuchal translucency thickness and normal karyotype compared with matched controls.

Authors:  R Buffin; A Fichez; E Decullier; A Roux; S Bin; D Combourieu; B Pastor-Diez; C Huissoud; J-C Picaud
Journal:  Ultrasound Obstet Gynecol       Date:  2021-04-07       Impact factor: 7.299

6.  First trimester screening using ultrasound and serum markers in Panamanians: Factors associated with adverse pregnancy outcomes.

Authors:  Tania T Herrera; Scarlett Sinisterra; Alcibiades Solis; Gabrielle B Britton
Journal:  J Res Med Sci       Date:  2014-05       Impact factor: 1.852

7.  Ultrasound and echocardiographic findings obtained in the second and third trimesters of gestation in fetuses with normal karyotype and increased nuchal translucency.

Authors:  Hanna Moczulska; Katarzyna Janiak; Maciej Słodki; Maria Respondek-Liberska
Journal:  J Ultrason       Date:  2013-03-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.